Similarly, treatment of FLT3L/poly I:C, which expands and induces the maturation and activation of CD103+ cDC1s at the tumor sites, has been shown to enhance anti-tumor responses and improve efficacy when combined with BRAF and PD-L1 blockade (93). The gene discussed is FLT3LG; the disease is neoplasm.